Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Maverick Capital Ltd.

Maverick Capital Ltd. lowered its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 3.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,211,138 shares of the company’s stock after selling 45,432 shares during the quarter. Maverick Capital Ltd. owned 1.39% of Day One Biopharmaceuticals worth $16,689,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Deerfield Management Company L.P. Series C boosted its holdings in Day One Biopharmaceuticals by 65.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock valued at $40,281,000 after purchasing an additional 1,157,825 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Day One Biopharmaceuticals by 517.0% in the 2nd quarter. AQR Capital Management LLC now owns 113,020 shares of the company’s stock valued at $1,557,000 after buying an additional 94,703 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter worth about $2,570,000. Point72 DIFC Ltd acquired a new stake in Day One Biopharmaceuticals during the second quarter worth about $124,000. Finally, Marshall Wace LLP raised its position in Day One Biopharmaceuticals by 20.1% during the second quarter. Marshall Wace LLP now owns 161,129 shares of the company’s stock valued at $2,220,000 after acquiring an additional 26,958 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 10,681 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $149,534.00. Following the completion of the sale, the chief executive officer now owns 98,932 shares of the company’s stock, valued at $1,385,048. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Jeremy Bender sold 10,681 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $149,534.00. Following the transaction, the chief executive officer now directly owns 98,932 shares in the company, valued at approximately $1,385,048. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Samuel C. Blackman sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total value of $320,200.00. Following the completion of the sale, the insider now owns 1,121,081 shares of the company’s stock, valued at $17,948,506.81. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,748 shares of company stock worth $1,009,272. Corporate insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Trading Up 1.6 %

Shares of Day One Biopharmaceuticals stock opened at $14.29 on Friday. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $18.07. The firm has a market capitalization of $1.25 billion, a PE ratio of -5.69 and a beta of -1.51. The firm’s 50-day moving average price is $14.15 and its 200 day moving average price is $14.49.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.70. The firm had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $0.90 million. On average, sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on DAWN shares. Piper Sandler restated an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. JPMorgan Chase & Co. decreased their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Finally, Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.